Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LIAN NASDAQ:MTEX NYSEAMERICAN:PHGE NYSEAMERICAN:VNRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLIANLianBio$0.05-7.1%$0.12$0.27▼$4.99$5.62M0.231.04 million shs35,200 shsMTEXMannatech$4.50-3.4%$5.08$3.80▼$12.45$8.99M0.727,629 shs13,939 shsPHGEBiomX$0.19-4.7%$0.55$0.18▼$13.70$2.34M1.35.39 million shs11.87 million shsVNRXVolitionRX$1.00-7.4%$1.68$0.99▼$16.00$9.32M1.12204,704 shs176,127 shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLIANLianBio-20.00%-49.37%-49.46%-54.10%+3.70%MTEXMannatech-3.43%+5.88%-11.59%-5.46%-44.49%PHGEBiomX-4.69%-5.50%-54.63%-82.97%-97.76%VNRXVolitionRX-7.41%-9.09%-18.70%-64.31%-93.20%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLIANLianBio$0.05-7.1%$0.12$0.27▼$4.99$5.62M0.231.04 million shs35,200 shsMTEXMannatech$4.50-3.4%$5.08$3.80▼$12.45$8.99M0.727,629 shs13,939 shsPHGEBiomX$0.19-4.7%$0.55$0.18▼$13.70$2.34M1.35.39 million shs11.87 million shsVNRXVolitionRX$1.00-7.4%$1.68$0.99▼$16.00$9.32M1.12204,704 shs176,127 shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLIANLianBio-20.00%-49.37%-49.46%-54.10%+3.70%MTEXMannatech-3.43%+5.88%-11.59%-5.46%-44.49%PHGEBiomX-4.69%-5.50%-54.63%-82.97%-97.76%VNRXVolitionRX-7.41%-9.09%-18.70%-64.31%-93.20%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLIANLianBio 0.00N/AN/AN/AMTEXMannatech 1.00SellN/AN/APHGEBiomX 2.00Hold$26.0013,656.61% UpsideVNRXVolitionRX 2.40Hold$28.002,700.00% UpsideCurrent Analyst Ratings BreakdownLatest PHGE, VNRX, MTEX, and LIAN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026MTEXMannatech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)7/1/2026MTEXMannatech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/18/2026VNRXVolitionRX Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.006/11/2026MTEXMannatech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/2/2026VNRXVolitionRX BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold5/26/2026MTEXMannatech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)(Data available from 7/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLIANLianBioN/AN/AN/AN/A$2.71 per shareN/AMTEXMannatech$108.04M0.08N/AN/A($2.75) per share-1.64PHGEBiomXN/AN/AN/AN/A($12.50) per shareN/AVNRXVolitionRX$1.73M4.99N/AN/A($5.30) per share-0.19Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLIANLianBio-$110.29M-$0.81N/AN/AN/AN/A-33.17%-30.19%N/AMTEXMannatech-$15.21M-$6.71N/AN/AN/A-11.97%-2,383.34%-40.24%N/APHGEBiomX-$36.20M-$3.21N/AN/AN/AN/AN/A-89.14%8/12/2026 (Estimated)VNRXVolitionRX-$23.36M-$0.56N/AN/AN/A-997.49%N/A-289.87%8/13/2026 (Estimated)Latest PHGE, VNRX, MTEX, and LIAN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2026Q2 2026VNRXVolitionRX-$0.70N/AN/AN/A$0.44 millionN/A5/20/2026Q1 2026PHGEBiomXN/A$7.38N/A$7.38N/AN/A5/14/2026Q4 2025MTEXMannatechN/A$0.49N/A$0.49N/A$24.92 million5/14/2026Q1 2026VNRXVolitionRX-$0.70-$0.97-$0.27-$0.97$1.52 million$0.99 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthLIANLianBioN/AN/AN/AN/AN/AMTEXMannatechN/AN/A-100.00%N/AN/APHGEBiomXN/AN/AN/AN/AN/AVNRXVolitionRXN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLIANLianBioN/A10.0610.06MTEXMannatechN/A1.090.59PHGEBiomXN/A1.241.24VNRXVolitionRXN/A0.330.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLIANLianBio74.85%MTEXMannatech12.98%PHGEBiomX40.57%VNRXVolitionRX8.09%Insider OwnershipCompanyInsider OwnershipLIANLianBio7.59%MTEXMannatech47.50%PHGEBiomX0.18%VNRXVolitionRX6.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLIANLianBio110108.06 million99.86 millionNot OptionableMTEXMannatech2501.93 million1.01 millionNot OptionablePHGEBiomX12011.80 million11.78 millionN/AVNRXVolitionRX808.63 million8.03 millionNot OptionablePHGE, VNRX, MTEX, and LIAN HeadlinesRecent News About These CompaniesVolitionRx Shareholders Approve Governance and Capital ChangesJuly 24 at 3:51 AM | theglobeandmail.comVolitionRX (NYSEAMERICAN:VNRX) Stock Price Passes Below 50-Day Moving Average - Time to Sell?July 17, 2026 | americanbankingnews.comVolitionRx (VNRX) Stock Gets Fair Value Boost As Analysts Split On Nu.Q ExecutionJuly 11, 2026 | finance.yahoo.comVolitionRx Announces Data Showing the Prognostic Value of its Nu.Q® Cancer TestJuly 7, 2026 | prnewswire.comVolitionRx partners with Sysmex to optimize Nu.Q® NETs assayJune 17, 2026 | msn.comVolitionRx Limited: VolitionRx Announces Collaboration with SysmexJune 17, 2026 | finanznachrichten.deVolitionRx Announces Collaboration with SysmexJune 17, 2026 | prnewswire.comVolitionRx Announces Pricing of $4.6 Million Public OfferingJune 7, 2026 | prnewswire.comVolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment MonitoringJune 3, 2026 | prnewswire.comVolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable MarketsMay 27, 2026 | prnewswire.comVolitionRx Limited (VNRX): 7 Best Rated Penny Stocks to Buy According to Wall Street AnalystsMay 24, 2026 | finance.yahoo.comVolitionRX Earnings Call Balances Breakthroughs and RisksMay 20, 2026 | tipranks.comVolitionRX Ltd (VNRX) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ...May 15, 2026 | finance.yahoo.comVolitionRX Earnings Call: Breakthrough Science, Cash Burn RiskMay 15, 2026 | tipranks.comVolitionRx Limited (VNRX) Q1 2026 Earnings Call TranscriptMay 15, 2026 | seekingalpha.comVolitionRx Limited Announces First Quarter 2026 Financial Results and Business UpdateMay 14, 2026 | prnewswire.comVolitionRx (VNRX) price target increased by 1,618.09% to 29.79May 14, 2026 | msn.comVolitionRX Ltd.May 12, 2026 | marketwatch.comVolitionRx Limited Schedules First Quarter 2026 Earnings Conference Call and Business UpdateMay 11, 2026 | prnewswire.comVolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in CatsMay 6, 2026 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePHGE, VNRX, MTEX, and LIAN Company DescriptionsLianBio NASDAQ:LIAN$0.05 0.00 (-7.14%) As of 07/24/2026LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.Mannatech NASDAQ:MTEX$4.50 -0.16 (-3.43%) As of 07/24/2026 03:32 PM EasternMannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas.BiomX NYSEAMERICAN:PHGE$0.19 -0.01 (-4.69%) As of 07/24/2026 04:10 PM EasternBiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.VolitionRX NYSEAMERICAN:VNRX$1.00 -0.08 (-7.41%) Closing price 07/24/2026 04:10 PM EasternExtended Trading$1.02 +0.02 (+1.90%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Plugging In: How Kinder Morgan Powers Up Profits TSMC’s Price Hikes Could Show Which AI Chip Stocks Have Real Pricing Power Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
